Decision Resources grows portfolio

Share this article:
Decision Resources has acquired Manhattan Research. 

The move will expand Decision Resources' global physician and consumer digital market research portfolio, according to a statement. Terms of the deal were not disclosed to the public.

“Part of Decision Resources' big goal is to grow our business both organically, and to build a stable of premier market research firms that focus on specific areas of the healthcare industry,” said Elizabeth Marshall, director of marketing at Decision Resources. 

Marshall cites Millennium Research Group and HealthLeaders as two examples of other research firms providing Decision Resources with a specialized focus: Millennium for medical devices and technology, and HealthLeaders for managed care. “We're looking at the bigger picture and the healthcare industry as a whole—we're offering clients an integrated model,” said Marshall. 

Manhattan Research will remain headquartered in New York, NY. Decision Resources is located in Waltham, MA.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?